Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

A new national guideline provides evidence-based recommendations for diagnosing, treating, and preventing pediatric ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that ...

CDC advisers recommend Merck's Enflonsia to protect babies from RSV, addressing the leading cause of infant hospitalization ...

Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine ...

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV ...

In its alert, the MHRA said: “Healthcare professionals should advise all recipients of Abrysvo and Arexvy that they should be ...

The letter, signed by 79 medical societies, expresses concern over recent federal immunization review policies and asks that ...

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

The Centers for Disease Control and Prevention's vaccine advisory committee voted on Thursday to recommend infants receive a ...